This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.




Mobile version  RSS  Subscribe  Unsubscribe  Archive  Media Kit |   AhHa B2B Search:     

Home   About AST   Education   Meetings & Events   Public Policy   Contact Us   Oct. 12, 2012

 


Virtual histology assessment of cardiac allograft vasculopathy following introduction of everolimus – results of a multicenter trial
American Journal of Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
In a 12-month multicenter Scandinavian study, 78 maintenance heart transplant (HTx) recipients randomized to everolimus with reduced calcineurin inhibitor (CNI) exposure or continued standard CNI-therapy underwent matched virtual histology (VH) examination to evaluate morphological progression of cardiac allograft vasculopathy (CAV). Parallel measurement of a range of inflammatory markers was also performed. More



PRESIDENT'S CORNER
Roslyn Mannon, MD

Talk is cheap


AST President, Dr. Roslyn Mannon is continuing to fight for the Immuno Bill. But talk is cheap, and in her latest blog post Dr. Mannon writes about how it takes action to influence public policy. She hopped a plane to Washington, DC last week and spoke directly to Capitol Hill about why this important legislation hasn't passed yet. And you won't believe what she found out.... Read and comment on this blog .

 SOCIETY NEWS


Plan activities, register donors and earn recognition from the WPFL Hospital Organ Donation Campaign
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The AST is a proud partner of the Workplace Partnership for Life (WPFL) Campaign. The goal of the campaign is to register 300,000 new donors nationally by May 2013. Hospitals have been challenged to go the extra mile during Phase II of this campaign to exceed that goal.

The challenge scorecard includes a list of outreach, education and donor registry activities with points assigned to each. Hospitals can record the number of times they complete each activity, and the form will automatically total their points toward bronze, silver and gold recognition in the hospital campaign. Hospitals must return their completed forms by May 15, 2013 to their WPFL hospital campaign contact at their OPO or DLA affiliate. OPOs and DLAs will report the results to HRSA, and hospitals will be recognized in a variety of ways beginning June 2013.

Start now and make the last seven months of this campaign your best! For those that haven't enrolled, it's not too late. Fill out and submit an enrollment form to or contact your OPO/DLA affiliate.


C1qScreen™: A New Research Tool for AMR Risk
Identify Antibodies That May Compromise Graft Survival
  • Detect Presence of Complement Fixing Antibodies
  • Investigate risk of developing Antibody Mediated Rejection (AMR)
Request a Complimentary Sample Kit!
FREE SAMPLE

For Research Use Only. Not for use in diagnostic procedures.


TEDx presentation on organ donation
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Recently, AST member Dr. Christopher Barry addressed a crowd at TEDx FlourCity, a day-long event in Rochester, N.Y., designed to catalyze positive local initiatives through conversation, collaboration and community building. Dr. Barry, a transplant surgeon at the University of Rochester Medical Center, gave a passionate presentation on "Giving the Gift of Life through Organ Donation."

The presentation (which you can view in full here) touched on the power of modern transplantation to impact people's lives and explored some common obstacles hindering organ donation rates. Please share as you deem appropriate. It's only through inspiring talks like these that we can encourage a viral movement of informed citizens to take direct action and sign up to be a life-saving organ donor.


Submit your abstracts to AST's Cutting Edge of Transplantation by Oct. 31
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
B Cells from Bedside to Bench to Bedside: A Comprehensive Look at B Cells and Antibodies in Transplantation
With so many recent advances on the biology of B cells and with antibody-mediated rejection having become one of the major hurdles to long-term transplant survival, it is time for clinicians and basic scientists to join forces to solve the clinical problem using the most up-to-date knowledge and technologies. View the full program and faculty list. Registration opens soon with 50 percent off deals if you register by Nov. 30!




 TRANSPLANT NEWS


Portable device points to better lung transplants
Fox News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Scientists have successfully tested a portable device to prepare lungs for transplant, potentially boosting the number of organs available and reducing the risk the operation will fail. The Organ Care System, which has been tested on 12 patients in Germany and Spain, allows donor lungs to be prepared and preserved for transplant at body temperature, keeping them in better condition than the usual practice of cooling them down, according to results of a study published in the Lancet.

Related articles:
Portable device points to better lung transplants (Medical Xpress)
Organ care system safe and feasible for lung transplant patients (Scientific American)
More

New immunosuppressants in pediatric solid organ transplantation
Current Opinion in Organ Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
There are currently trials underway investigating the use of eculizumab and bortezomib for treatment of antibody-mediated rejection as well as utilizing these agents as part of desensitization protocols. Minimal (or even monotherapy) maintenance immunosuppression regimens include monoclonal antibodies and fusion receptor proteins targeting different pathways (CD40–CD154, CD28–CD80/86, and LFA3–CD2 pathway). Phase III randomized controlled trials in adults are required before embarking on treatment of children. More



Preclinical efficacy and immunological safety of fr104, an antagonist anti-cd28 monovalent fab' antibody
American Journal of Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Antagonist anti-CD28 antibodies prevent T cell costimulation and differentiate from CTLA4Ig since they cannot block CTLA-4 and PDL-1 coinhibitory signals. They demonstrated efficacy in suppressing effector T cells while enhancing regulatory T cells function and immune tolerance. However, anti-CD28 antibodies devoid of immunotoxicity and with a good pharmacokinetic profile have not yet been developed. More

Transplanted nuclei and cell differentiation
Scientific American    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The nucleus of a cell from a frog's intestine is transplanted into a frog's egg and gives rise to a normal frog. Such experiments aid the study of how genes are controlled during embryonic development. More

Athena Diagnostics

Genetic testing can be a cost-effective way to increase the number of living related donor transplants. Mutational analysis may help direct long-term treatment plans, including pre-operative screening of potential kidney transplant recipients and living related donors.
more


Many back incentives to boost kidney donation
Renal & Urology News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
In Canada, more than 70 percent of 2,004 members of the public, 40 percent of 339 health professionals and 40 percent of 268 people with or affected by renal disease support the offering of financial incentives to increase kidney donations. However, only 45 percent, 14 percent and 27 percent, respectively, support monetary payments for living donors. More

A new transcutaneous bidirectional communication for monitoring implanted artificial heart using the human body as a conductive medium
Artificial Organs (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
A transcutaneous communication system (TCS) is a key technology for monitoring and controlling artificial hearts and other artificial organs in the body. In this study, researchers developed a new TCS that uses the human body as a conductive medium. Direct data exchange provides a higher level of communication security compared to that of wireless methods without physical constraints such as an external wire. More
 



AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Courtney Hodges, Content Editor, 972.402.2604   
Contribute news


This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
Oct. 5, 2012
Sept. 27, 2012
Sept. 20, 2012
Sept. 13, 2012






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063